Free Trial

Compass Therapeutics (CMPX) Stock Forecast & Price Target

Compass Therapeutics logo
$2.08 -0.14 (-6.31%)
Closing price 04:00 PM Eastern
Extended Trading
$2.08 +0.00 (+0.19%)
As of 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Compass Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
1
Buy
12

Based on 14 Wall Street analysts who have issued ratings for Compass Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a sell rating, 1 has given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for CMPX.

Consensus Price Target

$12.91
520.63% Upside
According to the 14 analysts' twelve-month price targets for Compass Therapeutics, the average price target is $12.91. The highest price target for CMPX is $30.00, while the lowest price target for CMPX is $6.00. The average price target represents a forecasted upside of 520.63% from the current price of $2.08.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CMPX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Compass Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CMPX Analyst Ratings Over Time

TypeCurrent Forecast
6/2/25 to 6/2/26
1 Month Ago
5/3/25 to 5/3/26
3 Months Ago
3/4/25 to 3/4/26
1 Year Ago
6/2/24 to 6/2/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$12.91$13.60$13.36$13.13
Forecasted Upside520.63% Upside593.88% Upside134.86% Upside510.47% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyBuy

CMPX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CMPX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Compass Therapeutics Stock vs. The Competition

TypeCompass TherapeuticsMedical CompaniesBroader Market
Consensus Rating Score
2.86
2.30
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside501.82% Upside1,731.94% Upside15.80% Upside
News Sentiment Rating
Positive News

See Recent CMPX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
6/1/2026
Stifel Nicolaus logo
Stifel Nicolaus
4 of 5 stars
Stephen Willey
Stephen Willey
5 of 5 stars
Set Target$6.00+167.26%
4/28/2026 DowngradeOutperformMarket Perform
4/28/2026
John Newman
3 of 5 stars
Lower TargetBuy$13.00 ➝ $7.00+285.67%
4/28/2026Reiterated RatingMarket Outperform$10.00+408.90%
4/27/2026Reiterated RatingBuy$24.00+1,149.99%
4/27/2026Reiterated RatingBuy$30.00+498.44%
4/20/2026 Reiterated RatingSell (D-)
3/24/2026Reiterated RatingBuy$12.00+141.69%
3/12/2026Reiterated RatingOverweight
3/5/2026Reiterated RatingBuy$9.00+62.75%
From the man who predicted 2008 crash… (Ad)

Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel

Watch Porter Stansberry's full briefing and learn how to prepare now
3/5/2026Reiterated RatingOutperform
2/13/2026 Initiated CoverageBuy$15.00+136.59%
12/3/2025 Initiated CoverageOutperform
11/26/2025 UpgradeStrong-Buy
10/6/2025 Set Target$10.00+170.27%
10/6/2025 Initiated CoverageOutperform$10.00+170.27%
4/1/2025 Reiterated RatingOutperform$8.00+257.14%
2/19/2025Initiated CoverageOverweight$12.00+278.55%
9/16/2024UpgradeNeutralBuy$5.00+203.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:12 PM ET.


CMPX Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Compass Therapeutics is $12.91, with a high forecast of $30.00 and a low forecast of $6.00.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There is currently 1 sell rating, 1 hold rating, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CMPX shares.

According to analysts, Compass Therapeutics's stock has a predicted upside of 520.63% based on their 12-month stock forecasts.

Over the previous 90 days, Compass Therapeutics's stock had 1 downgrade by analysts.

Analysts like Compass Therapeutics more than other "medical" companies. The consensus rating for Compass Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how CMPX compares to other companies.


This page (NASDAQ:CMPX) was last updated on 6/2/2026 by MarketBeat.com Staff.
From Our Partners